This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion (Figure 2). This is the fifth consecutive year of decreasing annual investment, with 2017 levels representing the lowest funding since 2005.
Click here for the full archive of past resource tracking reports.
AVAC’s 2018 annual state of the field report, No Prevention, No End! looks at today’s prevention crisis and offers context, analysis and strategy to turn that crisis around.
In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a collaboration with the International AIDS Society’s (IAS) Towards an HIV Cure initiative to review and allocate grants towards HIV cure research and analyze data on global funding. The working group released a report in July 2018, Global Investment in HIV Cure Research and Development in 2017: After Years of Rapid Growth Funding Increases Slow.
This four-pager explores stories about stakeholder engagement in the current suite of efficacy trials as well as stories around global support for vaccine research in the age of an expanded HIV prevention landscape.
In the new issue of Px Wire, AVAC gives our take on this year’s PEPFAR process for establishing the Country Operational Plans (COPs). These plans define what work will be done with PEPFAR money at the country level and how that work will be evaluated in each of the 63 countries that receive PEPFAR money.
This short excerpt from our AVAC Report 2017 contains two stories: an update on hormonal contraception and HIV risk, including what to look out for in 2018, and an explanation of the damage caused by the Trump Administration’s expanded Global Gag Rule, preventing any organization receiving US global health funding from advocating for abortion as a family planning method.
In this issue of Px Wire, we take a hard look at a host of major milestones coming up toward ambitious global targets for ending the epidemic. We also include detailed infographics on showing the status of oral PrEP rollout in the countries where trial sites are located, explaining the demographics of Africa’s “youth bulge” and its implications for the global response and more.
On the eve of World AIDS Day 2017, AVAC published its annual report on the state of the field. AVAC Report 2017: Mixed Messages and How to Untangle Them is a must-read for anyone tracking the progress of HIV prevention around the world. In this month’s episode of Px Pulse, AVAC’s Director of Strategy & Content Emily Bass shares highlights from the report and calls for action on the unfinished work of scaling up prevention.
AVAC is excited to share our annual “state of the field” report on biomedical prevention research and implementation. AVAC Report 2017: Mixed Messages and How to Untangle Them is straight talk about today’s complex context for HIV prevention. Read this report if you’ve wondered that there’s more rhetorical support than ever for HIV prevention but no more money? How can the world be “on the path to epidemic control” while human rights are trampled in many places, and rates of HIV diagnoses climb in others? How can scientists be so sure they know what women want, without doing research to find out?
For more from the report, including a link to all its graphics, visit avac.org/report2017.
In Px Wire, we preview part of the AVAC Report 2017, which includes a set of recommendations and priorities that keep funding and research crossing-cutting, strategic and responsive to people’s real-world needs. Check out the infographic, which provides a visual history of the DAIDS Networks and a look at what’s proposed for the next funding cycle.